Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. Following the announcement last month of their forthcoming new EP Floating ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback